Effects of Intravenously Administrated Omeprazole on Gastric Juice pH and Gastric Ulcer Scores in Adult Horses

Andrews, Frank M.; Frank, Nicholas; Sommardahl, Carla S.; Buchanan, Benjamin R.; Elliott, Sarah B.; Allen, Vern A.

doi:10.1892/0891-6640(2006)20[1202:eoiaoo]2.0.co;2

Cited by 23 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with some reports of minimal inter-individual variability in baseline gastric pH (Tellez et al, 2005;Andrews et al, 2006). Nevertheless, other studies have reported significant inter-horse variations (Daurio et al, 1999;JD Ruiz et al, 2012).…”

Section: Discussionsupporting

confidence: 89%

“…Other researchers found gastric pH increased above 4 during the first hour only in three out of six horses treated with 0.5 mg/Kg IV omeprazole (Andrews et al, 2006). In the present study, pH remained above 4 for up to 11 hours after injection of either 1 or 2 mg/Kg omeprazole; which is the minimum pH that should be maintained for as long as possible in order to improve the healing rate of gastric lesions (Armstrong, 2004).…”

Section: Discussionsupporting

confidence: 50%

“…They also reported a pH of 5.27 ± 1.74 before omeprazole was administered 23 hours after the 4 th daily dose was given. However, pH was very different among horses and time, whereas only 3 out of 6 horses had gastric pH above 4.0 one hour after omeprazole administration on the first day of the treatment, and it was above 4.0 in 5 of the 6 animals on day five (Andrews et al, 2006).…”

Section: Introductionmentioning

confidence: 88%

“…However, oral administration of medications in horses with gastrointestinal disorders such as gastric reflux or dysphagia is contraindicated, so intravenous (IV) administration of omeprazole is an alternative route to increase gastric pH (Rand et al, 2014). Andrews et al (2006) administered 0.5 mg/Kg IV omeprazole once daily for five days to six adult horses, and observed that gastric pH increased from 2 to 4.35 one hour after administration on the first day of the treatment. They also reported a pH of 5.27 ± 1.74 before omeprazole was administered 23 hours after the 4 th daily dose was given.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effects of two intravenous dose levels of omeprazole on the gastric juice pH of healthy horses

Ruiz

Ramírez²,

Lezcano³

2016

Rev Colomb Cienc Pecu

View full text Add to dashboard Cite

Efecto de dos niveles de dosis intravenosas de omeprazol sobre el pH del jugo gástrico de caballos sanos Efeito de dois níveis de doses intravenosas de omeprazol no suco gástrico pH cavalos saudáveisJhon D Ruiz * , MV, MSc, PhD; Juan E Ramírez, MVZ; Ángel Lezcano MVZ. Zootecnia, Universidad CES. Medellin, Colombia. (Received: March 29, 2015; accepted: June 8, 2016) doi: 10.17533/udea.rccp.v29n4a05 Summary Background: omeprazole suppresses gastric acid secretion and increases gastric juice pH by blocking the H+, K+ ATPase in the secretory membrane of parietal cells. Gastric juice pH below 4, long periods of no feed intake and stress are factors predisposing to gastric ulcers in horses. Objective: to determine the effect of 1 and 2 mg/Kg intravenous (IV) omeprazole on the gastric juice pH of Colombian Creole horses. Methods: seven horses were treated with two IV levels of omeprazole (1, and 2 mg/Kg body weight (BW)) in a crossover design. The omeprazole dose for each animal was reconstituted with 100 ml 0.9% NaCl. Gastric pH was measured using a portable pH-meter in stomach samples collected at time 0 (just before treatment), and 1, 2, 3, 5, 7, 9, 11, and 24 hours post-treatment. Results: the gastric pH at time 0 fluctuated from 1.6 to 3.2 in all horses. Both omeprazole doses (1 and 2 mg/Kg) significantly increased the gastric pH (pH>4.6) from 1 to 11 hours after the treatment. At 24 hours post-treatment, pH of the group treated with 1.0 mg/Kg significantly decreased to 2.8 ± 0.3, but remained elevated at 5.7 ± 0.87 for the group treated with 2 mg/Kg. Conclusion: the study demonstrated that a single IV omeprazole dose of 2 mg/Kg, but not 1 mg/Kg, maintained gastric pH above 4 during 24 hours. Grupo de Investigación en Ciencias (INCA-CES). Facultad de Medicina Veterinaria y

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 50%

Section: Introductionmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of two intravenous dose levels of omeprazole on the gastric juice pH of healthy horses

Ruiz

Ramírez²,

Lezcano³

2016

Rev Colomb Cienc Pecu

View full text Add to dashboard Cite

show abstract

“…Measuring intragastric pH has been widely accepted as a valid method for comparing and evaluating the efficacy of acid suppressants; however, the correlation between increased intragastric pH and outcome of acid‐related disorders has not been studied enough 1, 5, 6, 8, 9, 10, 11, 12. The aspiration of gastric juices, the placement of a pH electrode through a gastric fistula, and the placement of an pH catheter have been used as methods for measuring gastric pH 7, 8.…”

mentioning

confidence: 99%

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

Hwang

Jeong

Song

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundEsomeprazole is an S‐enantiomer of omeprazole that has favorable pharmacokinetics and efficacious acid suppressant properties in humans. However, the pharmacokinetics and effects on intragastric pH of esomeprazole in dogs have not been reported.ObjectiveTo determine the pharmacokinetics of esomeprazole administered via various routes (PK study) and to investigate the effect of esomeprazole on intragastric pH with a Bravo pH monitoring system (PD study).AnimalsSeven adult male Beagle dogs and 5 adult male Beagle dogs were used for PK and PD study, respectively.MethodsBoth studies used an open, randomized, and crossover design. In the PK study, 7 dogs received intravenous (IV), subcutaneous (SC), and oral doses (PO) of esomeprazole (1 mg/kg). Each treatment period was separated by a washout period of at least 10 days. Esomeprazole plasma concentrations were measured by HPLC/MS/MS. In the efficacy study, intragastric pH was recorded without medication (baseline pH) and following IV, SC, and PO esomeprazole dosing regimens (1 mg/kg) in 5 dogs.ResultsThe bioavailability of esomeprazole administered as PO enteric‐coated granules and as SC injections was 71.4 and 106%, respectively. The half‐life was approximately 1 hour. Mean ± SD percent time intragastric pH was ≥3 and ≥4 was 58.9 ± 21.1% and 40.9 ± 17.3% for IV group, 75.8 ± 16.4% and 62.7 ± 17.7% for SC group, 88.2 ± 8.9% and 82.5 ± 7.7% for PO group, and 12.5 ± 3.6% and 3.7 ± 1.8% for baseline. The mean percent time with intragastric pH was ≥3 or ≥4 was significantly increased regardless of the dosing route (P < .05).ConclusionThe PK parameters for PO and SC esomeprazole administration were favorable, and esomeprazole significantly increased intragastric pH after IV, PO, and SC administration. IV and SC administration of esomeprazole might be useful when PO administration is not possible. No significant adverse effects were observed.

show abstract

A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole

Gough¹,

Hallowell

Rendle³

2020

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Background: Equine squamous gastric disease (ESGD) is a highly prevalent disease in horses, particularly in elite athletes. Some horses respond slowly, or fail to respond, to the licensed treatment, oral omeprazole (ORLO). Objectives:To compare rates of ESGD healing and improvement between ORLO and a long-acting injectable omeprazole preparation (LAIO). Study design: Retrospective clinical study. Methods: The case records and gastroscopy images of horses presenting to Rainbow Equine Hospital over a 12-month period were reviewed, with images being reviewed blind by one of the authors (David Rendle). Treatment responses were compared between horses that received 2 or 4 injections of 4 mg/kg LAIO at weekly intervals, and horses that received ORLO at 4 mg/kg PO SID for 4 weeks. Data were compared using a Mann-Whitney test with post hoc Dunn's test, chi-squared test or Fisher's exact test. Results: Fifty-six horses met the inclusion criteria: 29 received LAIO and 27 received ORLO. Treatment groups were comparable in terms of signalment and ESGD lesions.There was a difference in rate of healing when LAIO and ORLO treatment groups were compared at 28 days (LAIO-97%; ORLO-67%; p = .005; OR = 14(1.8-158)), but no difference between LAIO at 14 days and ORLO at 28 days (LAIO-86%; ORLO-67%; p = .12; OR = 3.1 (0.9-10)). Five localised and self-limiting injection site reactions were identified in 3 horses out of 98 injections (5.1%). Main limitations:The study was limited by its retrospective nature, absence of randomisation and limited numbers. Conclusions:Four weeks of treatment with LAIO resulted in better rates of ESGD healing than 4 weeks of ORLO. Larger more robust studies of LAIO are warranted. K E Y W O R D S gastrointestinal, horse, proton pump inhibitor, stomach How to cite this article: Gough S, Hallowell G, Rendle D.A study investigating the treatment of equine squamous gastric disease with long-acting injectable or oral omeprazole.

show abstract

Effects of Intravenously Administrated Omeprazole on Gastric Juice pH and Gastric Ulcer Scores in Adult Horses

Cited by 23 publications

References 23 publications

Effects of two intravenous dose levels of omeprazole on the gastric juice pH of healthy horses

Effects of two intravenous dose levels of omeprazole on the gastric juice pH of healthy horses

Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs

A study investigating the treatment of equine squamous gastric disease with long‐acting injectable or oral omeprazole

Contact Info

Product

Resources

About